Merck Gains Support for Broader Use of Preventive RSV Treatment

By Connor Hart

 

Merck's preventive treatment for respiratory syncytial virus cleared a regulatory hurdle, with a European Medicines Agency committee recommending an expanded indication.

The Committee for Medicinal Products for Human Use adopted a positive opinion recommending the use of the treatment, called Enflonsia, to prevent respiratory syncytial virus, or RSV, a lower respiratory tract disease in certain children up to 24 months of age who remain at increased risk for severe disease through their second RSV season, Merck said Friday.

The recommendation will now be reviewed by the European Commission for marketing authorization in the European Union, Iceland, Liechtenstein and Norway. A final decision is expected within the next two months, according to Merck.

"For some children, the risk of severe RSV does not end after their first RSV season and they remain at increased risk for serious cases of RSV-related bronchiolitis or pneumonia that can require hospitalization," said Macaya Douoguih, therapeutic area head of global clinical development at Merck Research Laboratories.

The positive opinion is an important step toward bringing Enflonsia to children in the region who remain at increased risk, Douoguih said.

 

Write to Connor Hart at connor.hart@wsj.com

 

(END) Dow Jones Newswires

November 13, 2026 08:28 ET (13:28 GMT)

Copyright (c) 2026 Dow Jones & Company, Inc.

The articles, information, and content displayed on this webpage may include materials prepared and provided by third parties. Such third-party content is offered for informational purposes only and is not endorsed, reviewed, or verified by Morningstar.

Morningstar makes no representations or warranties regarding the accuracy, completeness, timeliness, or reliability of any third-party content displayed on this site. The views and opinions expressed in third-party content are those of the respective authors and do not necessarily reflect the views of Morningstar, its affiliates, or employees.

Morningstar is not responsible for any errors, omissions, or delays in this content, nor for any actions taken in reliance thereon. Users are advised to exercise their own judgment and seek independent financial advice before making any decisions based on such content. The third-party providers of this content are not affiliated with Morningstar, and their inclusion on this site does not imply any form of partnership, agency, or endorsement.

Popular

Sponsor Center